ORUM - Asset Resilience Ratio
ORUM (475830) has an Asset Resilience Ratio of 82.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 475830 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how ORUM's Asset Resilience Ratio has changed over time. See what is ORUM's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ORUM's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ORUM (475830) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.44 Billion | 3.88% |
| Short-term Investments | ₩151.02 Billion | 78.85% |
| Total Liquid Assets | ₩158.45 Billion | 82.74% |
Asset Resilience Insights
- Very High Liquidity: ORUM maintains exceptional liquid asset reserves at 82.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ORUM Industry Peers by Asset Resilience Ratio
Compare ORUM's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for ORUM (2022–2024)
The table below shows the annual Asset Resilience Ratio data for ORUM.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 76.51% | ₩117.70 Billion ≈ $79.76 Million |
₩153.84 Billion ≈ $104.25 Million |
-1.78pp |
| 2023-12-31 | 78.29% | ₩126.66 Billion ≈ $85.83 Million |
₩161.78 Billion ≈ $109.64 Million |
+21.51pp |
| 2022-12-31 | 56.78% | ₩12.09 Billion ≈ $8.19 Million |
₩21.28 Billion ≈ $14.42 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more